Precision BioSciences (NASDAQ:DTIL) stock gains as company reports promising Phase 1 trial results for its Hepatitis B gene ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...
Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...
News Medical on MSN9h
Novel therapeutic approaches targeting the Wnt pathway in hepatocellular carcinomaHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates.
Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...
As many as 140,000 bereaved parents, children and siblings of infected blood scandal victims may claim compensation under new ...
Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...
IntroductionHepatocellular carcinoma (HCC) is one of the deadliest cancers globally, with increasing incidence and mortality rates. It arises from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback